Oncology drug discovery applications using the FMAT 8100 HTS system.
High-throughput screening (HTS) for potential anticancer agents requires a broad portfolio of assay platforms that may include kinase enzyme assays, protein-protein binding assays, and functional cell-based apoptosis assays. The authors have explored the use of fluorometric microvolume assay technology (the FMAT 8100 HTS System) in three distinct homogeneous HTS assays: (1). a Src tyrosine kinase enzyme assay, (2). a Grb2-SH2 protein-peptide interaction assay, and (3). an annexin V binding apoptosis assay. Data obtained from all three assays suggest that the FMAT system should facilitate the implementation of homogeneous assays for a wide variety of molecular targeted and cell-based screens.
Lee
Jennifer Y
JY
Novartis Pharmaceuticals Corporation, NJ 07901, USA.
Miraglia
Sheri
S
Yan
Xiongwei
X
Swartzman
Elana
E
Cornell-Kennon
Susan
S
Mellentin-Michelotti
Julia
J
Bruseo
Charles
C
France
Dennis S
DS
D048868:Adaptor Proteins, Signal Transducing; D017304:Annexin A5 / Q000032:analysis; D000970:Antineoplastic Agents / Q000032:analysis* / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D001681:Biological Assay / Q000295:instrumentation* / Q000379:methods; D051380:GRB2 Adaptor Protein; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010600:Pharmacology / Q000295:instrumentation* / Q000379:methods; D011506:Proteins / Q000032:analysis; D019061:src-Family Kinases / Q000032:analysis
D048868:Adaptor Proteins, Signal Transducing; D017304:Annexin A5; D000970:Antineoplastic Agents; D051380:GRB2 Adaptor Protein; C495948:GRB2 protein, human; D011506:Proteins; D019061:src-Family Kinases